MEDRx USA

MEDRx USA is a clinical-stage pharmaceutical company specializing in the development of innovative transdermal drug delivery systems. As the United States subsidiary of the Japanese firm MEDRx Co., Ltd., the company leverages its proprietary Ionic Liquid Transdermal System (ILTS) and Nano-sized Colloid Transdermal System (NCTS) platforms to create patch-based versions of established drugs. Their pipeline focuses on pain management and central nervous system disorders, with lead candidates including MRX-5LBT for postherpetic neuralgia and MRX-1OXT, a transdermal oxycodone for chronic pain. By utilizing ionic liquid technology, MEDRx enhances the solubility and skin permeability of drugs that are traditionally difficult to deliver topically. The company's mission is to improve patient quality of life by providing delivery methods that offer stable blood concentration levels and reduced systemic side effects.